2561-25-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Fluorophenoxy)-4-nitrobenzene is used as an intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity. Its ability to be modified and incorporated into more complex molecules makes it a versatile building block for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(4-Fluorophenoxy)-4-nitrobenzene is utilized as a starting material for the production of different agrochemicals. Its chemical properties allow it to be a key component in the creation of compounds that can be used in the agricultural industry for pest control and crop protection.
Used in Dye Industry:
1-(4-Fluorophenoxy)-4-nitrobenzene is also employed in the dye industry as a crucial intermediate for the production of various dyes. Its specific chemical characteristics enable the creation of a wide range of colors and hues, contributing to the diversity of dyes available for different applications.
Used in Organic Synthesis:
1-(4-Fluorophenoxy)-4-nitrobenzene is used as a building block in organic synthesis, where it serves as a starting point for the development of new chemical compounds. Its unique structure and properties make it a valuable asset in the synthesis of complex organic molecules for various applications.
Used in Medicinal Chemistry Research:
Given its demonstrated biological activity, 1-(4-Fluorophenoxy)-4-nitrobenzene is used in medicinal chemistry research as a potential starting material for the development of new drugs. Its properties and reactivity make it a promising candidate for further investigation and potential application in the treatment of various medical conditions.

InChI:InChI=1/C12H8FNO3/c13-9-1-5-11(6-2-9)17-12-7-3-10(4-8-12)14(15)16/h1-8H

Upstream product

• 371-41-5 4-Fluorophenol 
• 100-00-5 4-chlorobenzonitrile 
• 586-78-7 para-nitrophenyl bromide 
• 350-46-9 4-Fluoronitrobenzene 
• 636-98-6 p-nitrobenzene iodide 

Downstream Products

• 1367127-11-4 C₁₉H₁₄FNO₄ 
• 1367125-14-1 6-(4-(4-fluorophenoxy)phenyl)-4-(hydroxymethyl)-N-(2-(piperidin-1-yl)ethyl)picolinamide 
• 1367127-13-6 C₁₉H₁₅FN₂O₂ 
• 1367127-15-8 C₁₉H₁₃FN₂O 
• 1367127-17-0 C₁₉H₁₄FN₅O 
• 1367127-19-2 C₂₂H₁₈FN₅O₃ 
• 1367125-43-6 2-(5-(2-(4-(4-fluorophenoxy)phenyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)acetamide 
• 1367127-68-1 C₁₈H₁₀ClFN₂O 
• 1367127-70-5 C₃₀H₁₈F₂N₂O₂ 
• 1367127-72-7 C₂₀H₁₃FN₂O 
• 1367127-74-9 C₂₀H₁₅FN₂O₃ 
• 1367125-24-3 (R)-2-(1,2-dihydroxyethyl)-6-(4-(4-fluorophenoxy)phenyl)isonicotinamide 
• 1367127-76-1 C₂₉H₂₉FN₂O₅ 
• 1367127-78-3 C₃₀H₃₁FN₂O₅ 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY

The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide

Topoisomerase II (TOP2) poisons as anticancer drugs work by trapping TOP2 cleavage complexes (TOP2cc) to generate DNA damage. Repair of such damage by tyrosyl DNA phosphodiesterase 2 (TDP2) could render cancer cells resistant to TOP2 poisons. Inhibiting TDP2, thus, represents an attractive mechanism-based chemosensitization approach. Currently known TDP2 inhibitors lack cellular potency and/or permeability. We report herein two novel subtypes of the deazaflavin TDP2 inhibitor core. By introducing an additional phenyl ring to the N-10 phenyl ring (subtype 11) or to the N-3 site of the deazaflavin scaffold (subtype 12), we have generated novel analogues with considerably improved biochemical potency and/or permeability. Importantly, many analogues of both subtypes, particularly compounds 11a, 11e, 12a, 12b, and 12h, exhibited much stronger cancer cell sensitizing effect than the best previous analogue 4a toward the treatment with etoposide, suggesting that these analogues could serve as effective cellular probes.

Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels

Both N- and T-type calcium ion channels have been implicated in pain transmission and the N-type channel is a well-validated target for the treatment of neuropathic pain. An SAR investigation of a series of substituted aminobenzothiazoles identified a subset of five compounds with comparable activity to the positive control Z160 in a FLIPR-based intracellular calcium response assay measuring potency at both CaV2.2 and CaV3.2 channels. These compounds may form the basis for the development of drug leads and tool compounds for assessing in vivo effects of variable modulation of CaV2.2 and CaV3.2 channels.

CsF/clinoptilolite: An efficient solid base in SNAr and copper-catalyzed Ullmann reactions

CsF/clinoptilolite was found to be an efficient solid base catalyst for both SNAr and Ullmann ether reactions. A general and efficient one-step procedure was developed for the synthesis of biaryl ethers via direct coupling of electron-deficient aryl halides to phenols using CsF/clinoptilolite. The protocol was also applied to electron-rich aryl halides by addition of a catalytic amount of copper oxide nanoparticles. Both SNAr and Ullmann reactions were rapid and provided good to excellent yields.

Synthesis and biological evaluation of pentanedioic acid derivatives as farnesyltransferase inhibitors

Structure-based virtual screening of a commercial library identified pentanedioic acid derivatives (6 and 13b) as a kind of novel scaffold farnesyltransferase inhibitors (FTIs). Chemical modifications of the lead compounds, biological assays and analysis of the structure-activity relationships (SAR) were conducted to discover more potent FTIs. Some of them displayed excellent inhibition against FTase, and among them, the most active compound 13n with an IC50 value of 0.0029 μM and SAR analysis might be helpful to the discovery of more potent FTIs. This journal is

BENZIMIDAZOLE DERIVATIVES AND USE THEREOF

The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: and pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein W1, W2, W3, W4, U, G, m, R1, and R2 are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II to V as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.

Microwave assisted synthesis of selected diaryl ethers under Cu(I)-catalysis

A practical synthesis of diaryl ethers has been achieved from cross coupling reaction between aryl halides and phenols under Cu(I)-catalysis and using ACHN as a ligand. The presence of catalysis and microwave-assistance benefitted the synthesis by increasing the yield of diaryl ethers with a reduction of reaction time.

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

On the frontier between nucleophilic aromatic substitution and catalysis

A study on the arylation of heteroatom nucleophiles by using activated haloarenes, with or without metal catalysts, is reported. A discussion concerning the involvement of traces of metals is presented, supported by an unexpected ''ligand'' effect in the absence of added metal catalysts. We believe that the frontier between nucleophilic aromatic substitution and catalysis will likely prove to be much harder to delimit than is generally thought. S NAr or catalysis? A study on the arylation of heteroatom nucleophiles by using activated haloarenes, with or without added metal catalysts, is reported. A discussion concerning the involvement of traces of metals is presented, supported by an unexpected "ligand" effect in the absence of added metal catalysts (see scheme, EWG=electron-withdrawing group).

HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS

The invention relates to aryl substituted compounds of Formula (I) : and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein Het, G, A, R, and n are defined as set forth in the specification. The invention is also directed to the use